– CANADA, Toronto – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, today announced the appointment of David Bassin to its Board as an Independent Director.
About David Bassin
David Bassin brings a wealth of expertise and experience in the healthcare industry, particularly in the field of wound care. As the founder of GIO Advisory LLC, he has provided invaluable advisory services to numerous companies and private equity firms based on his extensive background in healthcare, spanning pharmaceutical/device, payer, and provider services. Most recently, Bassin served as the CEO of Healogics, the foremost provider of wound care services in the US, operating over 630 wound care centers and 300 providers. He successfully restructured and refocused the business during his tenure, resulting in strong earnings growth before he transitioned into advisory services. Before his role as CEO, Bassin served as the CFO of Healogics, contributing to the company’s financial growth and success. Bassin’s impressive career also includes significant roles in other healthcare organizations. He served as the CFO of eviCore Healthcare, Inc., where he oversaw multiple dividend recapitalizations and facilitated a merger with the company’s largest competitor, leading to the creation of a company with over 3,000 employees. Additionally, Bassin held the position of CFO at InVentiv Health, Inc., a provider of services to pharmaceutical companies, where he successfully managed a high-growth company and orchestrated a go-private transaction valued at over $1 billion, and delivered a significant premium to its shareholders.
David Bassin said, “Over 6.5 million patients are living with wounds. As an industry, we need to continue to develop new solutions that improve wound care treatment effectiveness and efficiency. With a global drive to improve outcomes, reduce costs, and minimize antibiotic usage, MolecuLight’s point-of-care devices have demonstrated their ability to address these critical clinical needs effectively. I am deeply impressed by the organization, the technology’s alignment with market demands, and the significant market traction they have achieved. I am eager to contribute to their growth and help them achieve their ambitious goals.”
About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s commercial devices, which include the MolecuLight I :X and DX fluorescence imaging systems and their accessories are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT codes for physician work to achieve “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department and Ambulatory Surgical Center settings through an Ambulatory Payment Classification assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics, and other key industrial markets.
For more information: https://moleculight.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
